Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer
- PMID: 17955238
- DOI: 10.1007/s00259-007-0612-1
Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer
Abstract
Purpose: We sought to identify prognostic factors-including positron emission tomography (PET) parameters-in patients with previously untreated squamous carcinoma of the uterine cervix and MRI- or CT-defined pelvic or para-aortic lymph node (PLN or PALN) metastasis.
Materials and methods: Patients with untreated squamous cell cervical cancer and PLN or PALN metastasis detected by CT/MRI were enrolled. FDG-PET scans were performed for primary staging. Prognostic variables were investigated by univariate and multivariate analyses. Five-year recurrence-free and 5-year overall survivals (RFS and OS) were evaluated using the Kaplan-Meier method.
Results: A total of 70 patients [54 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I or II, and 16 patients with stage III or IV] were eligible. Follow-up ranged from 26.1 to 71.6 months. In multivariate analysis, FIGO stage > or =III (5-year RFS, p = 0.008; 5-year OS, p = 0.008) was a significant prognostic factor for both RFS and OS. In addition, SUV(max) for PALN (dichotomized by 3.3) was significantly associated with OS (p = 0.012) and marginally with RFS (p = 0.078). The presence of SUV(max) > or = 3.3 at PALN or FIGO stage > or =III were significantly associated with both recurrence [5-year RFS; HR = 4.52, 95% confidence interval (CI) = 1.73-11.80] and death (5-year OS; HR = 6.04, 95% CI = 1.97-18.57).
Conclusion: SUV(max) > or = 3.3 for PALN and FIGO stage > or =III were significant adverse factors in patients with primary squamous cervical carcinoma and PLN or PALN metastasis detected by CT/MRI.
Similar articles
-
Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.Medicine (Baltimore). 2016 Mar;95(9):e2992. doi: 10.1097/MD.0000000000002992. Medicine (Baltimore). 2016. PMID: 26945420 Free PMC article.
-
Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.Cancer. 2010 Mar 15;116(6):1469-75. doi: 10.1002/cncr.24972. Cancer. 2010. PMID: 20108309
-
FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma.Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):489-93. doi: 10.1016/s0360-3016(02)04521-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12738325
-
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. doi: 10.1016/s0360-3016(02)04401-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654434 Review.
-
Diagnostic accuracy of preoperative 18F-FDG PET or PET/CT in detecting pelvic and para-aortic lymph node metastasis in patients with endometrial cancer: a systematic review and meta-analysis.Arch Gynecol Obstet. 2019 Sep;300(3):519-529. doi: 10.1007/s00404-019-05207-8. Epub 2019 Jun 4. Arch Gynecol Obstet. 2019. PMID: 31165242
Cited by
-
Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer.Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):674-81. doi: 10.1007/s00259-013-2626-1. Eur J Nucl Med Mol Imaging. 2014. PMID: 24233005
-
Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix.Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1862-1869. doi: 10.1007/s00259-017-3729-x. Epub 2017 May 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28534183
-
FDG-PET in gynaecological cancers: recent observations.Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2133-9. doi: 10.1007/s00259-008-0929-4. Eur J Nucl Med Mol Imaging. 2008. PMID: 18779962 Review. No abstract available.
-
Advances in diagnosis and treatment of metastatic cervical cancer.J Gynecol Oncol. 2016 Jul;27(4):e43. doi: 10.3802/jgo.2016.27.e43. J Gynecol Oncol. 2016. PMID: 27171673 Free PMC article. Review.
-
Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1270-8. doi: 10.1007/s00259-010-1417-1. Epub 2010 Mar 20. Eur J Nucl Med Mol Imaging. 2010. PMID: 20306032